At ASH, doctors acclaim new sickle cell gene therapies, but are cautious on details
Bio Pharma Dive
DECEMBER 13, 2023
Uptake of Casgevy and Lyfgenia may be slow despite their dramatic benefit, physicians said, citing complexities in treatment, manufacturing and reimbursement.
Let's personalize your content